ExpressionEdits is pioneering advancements in protein expression through its innovative AI-driven intronization technology. This approach focuses on optimizing genetic syntax, which allows for the production of proteins that have previously been difficult to express using traditional methods. By leveraging the role of introns—once deemed "junk DNA"—the company enhances gene expression without compromising the integrity of the original genetic design. Their methodology addresses the limitations of conventional techniques, such as codon optimization and the use of strong viral promoters, which often yield insufficient quantities of therapeutic proteins.

At the core of ExpressionEdits' technology is the Genetic Syntax Engine, a computational platform that refines genetic grammar to improve transgenic design. This engine utilizes advanced artificial intelligence and deep biological insights to predict the performance of transgenes and facilitate their redesign, ultimately unlocking protein expression across various therapeutic applications. The company is also focused on developing a pipeline of high-value protein therapeutics, aiming to overcome existing production challenges and support gene therapy optimization. Through collaborations and partnerships, ExpressionEdits seeks to enhance the potency and precision of gene therapies while maintaining the core designs of the genetic constructs.

United Kingdom

Getting genetic syntax right.

With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach.


ExpressionEdits

Company Details